Stockscreener 앱 받기
20.73
0.72%
-0.15
시간 외 거래:
20.71
-0.02
-0.10%
전일 마감가:
$20.88
열려 있는:
$20.9
하루 거래량:
91,801
Relative Volume:
1.05
시가총액:
$1.20B
수익:
-
순이익/손실:
$-75.28M
주가수익비율:
-10.39
EPS:
-1.9957
순현금흐름:
$-57.45M
1주 성능:
-4.38%
1개월 성능:
+9.68%
6개월 성능:
+5.34%
1년 성능:
+24.99%
1일 변동 폭
$20.54
$21.00
1주일 범위
$20.10
$21.86
52주 변동 폭
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
OCS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
20.73 | 1.21B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
(OCS) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Analyzing ABVC BioPharma (NASDAQ:ABVC) & Oculis (NASDAQ:OCS) - Defense World
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Yahoo Finance
Oculis (NASDAQ:OCS) Trading Down 6%Should You Sell? - MarketBeat
Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know - Zacks Investment Research
Oculis (NASDAQ:OCS) Trading 7% HigherHere's What Happened - MarketBeat
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan
Lifesci Capital Weighs in on Oculis FY2025 Earnings - Defense World
Lifesci Capital Forecasts Oculis FY2025 Earnings - MarketBeat
Will Oculis Holding AG stock benefit from commodity prices2025 Volume Leaders & Community Consensus Trade Signals - Newser
Is Oculis Holding’s New Equity Shelf Shaping a More Flexible Capital Strategy for OCS Investors? - simplywall.st
Oculis (NASDAQ:OCS) Coverage Initiated at Lifesci Capital - MarketBeat
How analysts revise price targets for Oculis Holding AG (CR5) stockMarket Movers & Low Drawdown Momentum Ideas - Newser
Why Oculis Holding AG (CR5) stock is upgraded to buyMarket Activity Report & Weekly Chart Analysis and Guides - Newser
How Oculis Holding AG Equity Warrant stock performs in interest rate cycles2025 Winners & Losers & Verified Swing Trading Watchlists - Newser
LifeSci Capital Initiates Coverage of Oculis Holding (OCS) with Outperform Recommendation - Nasdaq
Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know - sharewise.com
Liquidity Mapping Around (OCS) Price Events - news.stocktradersdaily.com
Why Oculis Holding AG stock could benefit from AI revolution2025 Major Catalysts & AI Driven Price Predictions - moha.gov.vn
US Market Recap: Can Oculis Holding AG stock deliver surprise earnings beatJuly 2025 Final Week & Reliable Entry Point Trade Alerts - moha.gov.vn
Oculis (OCS) files transaction notice for director RSU vesting dated Nov. 25, 2025 - Stock Titan
Can Oculis Holding AG stock deliver surprise earnings beat - BỘ NỘI VỤ
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyTrade Entry Report & Smart Swing Trading Techniques - BỘ NỘI VỤ
How strong is Oculis Holding AG stock balance sheetQuarterly Trade Report & Entry Point Confirmation Signals - BỘ NỘI VỤ
Oculis reports Q3 EPS (32c), consensus (41c) - MSN
Oculis (NASDAQ: OCS) to Run Global PIONEER Privosegtor Trials in AON and NAION - Stock Titan
Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $39.80 - Defense World
Cash per share of Oculis Holding AG – FWB:CR5 - TradingView
Why (OCS) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Will Oculis Holding AG stock keep outperforming rivalsTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Why millennials buy Oculis Holding AG (CR5) stockJuly 2025 Outlook & Stock Portfolio Risk Management - newser.com
Is Oculis Holding AG Equity Warrant stock a good choice for value investorsWeekly Trade Recap & Real-Time Stock Movement Alerts - newser.com
Is Oculis Holding AG Equity Warrant stock oversold or undervaluedJuly 2025 Trends & Risk Controlled Daily Trade Plans - newser.com
What dividend safety score for Oculis Holding AG Equity Warrant stockPrice Action & Expert Curated Trade Ideas - newser.com
Exit strategy if you’re trapped in Oculis Holding AG Equity WarrantQuarterly Market Summary & AI Forecast for Swing Trade Picks - newser.com
Will Oculis Holding AG (CR5) stock hit Wall Street targets2025 Growth vs Value & Real-Time Volume Triggers - newser.com
Can Oculis Holding AG stock sustain market leadershipMarket Growth Report & Community Trade Idea Sharing - newser.com
What moving averages say about Oculis Holding AG2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Will Oculis Holding AG stock deliver shareholder valueQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Why Oculis Holding AG Equity Warrant stock remains resilientEarnings Recap Summary & High Conviction Buy Zone Alerts - newser.com
Oculis Holding AG Equity Warrant stock trend outlook and recovery pathMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Oculis price target raised to $42 from $36 at H.C. Wainwright - MSN
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):